Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

GSK, other drugmakers bet on post-Brexit UK science

share with twitter share with LinkedIn share with facebook
share via e-mail
12/06/2017 | 01:21pm CET
FILE PHOTO: The logo of AstraZeneca is seen on medication packages in a pharmacy in London

Britain won a vote of confidence from its economically important life sciences sector on Wednesday as several major drug companies committed to invest in the country under the government's industrial strategy plans after Brexit.

The move is welcome news for Prime Minister Theresa May, who has struggled to win over large sections of industry as Britain prepares to leave the European Union.

Thanks to the strength of UK universities and the presence of two major pharmaceuticals companies in GlaxoSmithKline and AstraZeneca, the drugs industry has been a bright spot in the British economy for many years.

But the highly regulated sector faces potential obstacles to trade as a result of Brexit unless London and Brussels manage to align regulatory regimes for medicines.

In a bid to soften the blow, the government has backed a report by immunologist and geneticist John Bell designed to boost the pharmaceutical sector via fresh public-private collaborations.

That has paved the way for the Life Sciences Sector Deal, which will see GSK invest 40 million pounds of new money in genomic research, including a plan to sequence DNA from all 500,000 volunteer participants enrolled in UK Biobank, the world's most detailed biomedical database.

GSK's head of research Patrick Vallance said the deal showed Britain remained an attractive place for drug discovery, but he cautioned: "The UK needs to recognise going forward that science is an international endeavour, not a parochial endeavour."

Other investments by pharma companies include plans by Johnson & Johnson and the Medicines Co to work on new clinical trials and genetic research by AstraZeneca.

U.S. drugmaker Merck & Co had already announced plans to expand UK research operations under the deal last week.

In all, the government said the deal brought together existing and future commitments by 25 global organisations.

Other companies in discussions with the government about investments include Philips, Roche Diagnostics, Siemens, GE Healthcare and Toshiba Medical Systems.

As a key part of the deal, the government said it was committed to increasing investment in R&D to 2.4 percent of GDP by 2027 and 3 percent over the longer term.

(Reporting by Ben Hirschler; Editing by Gareth Jones and Louise Heavens)

By Ben Hirschler

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA
02:11p PIERIS PHARMACEUTICALS : Announces Ethics and Regulatory Clearance to Begin Clin..
01:27p Merck raises stakes in lung cancer as rivals close in
11:56a ASTRAZENECA : Quality control of biological pharmaceuticals
12/10 ASTRAZENECA : ’s CALQUENCE® (acalabrutinib) Shows Potential in Chronic Lym..
12/09 ASTRAZENECA : ’s CALQUENCE® (acalabrutinib) Demonstrates Activity in Relap..
12/08 ASTRAZENECA : to highlight its commitment to blood cancers at the 2017 American ..
12/07 ASTRAZENECA : Researchers at AstraZeneca Report Findings in Chemical Biology (Id..
12/07 ASTRAZENECA : Reports on Non-Small Cell Lung Cancer Findings from AstraZeneca Pr..
12/07 ASTRAZENECA : Reports from AstraZeneca Describe Recent Advances in Capsaicin (XE..
More news
News from SeekingAlpha
12/09 3 THINGS IN BIOTECH YOU SHOULD LEARN : December 9, 2017
12/07 Pieris on go with early-stage study of inhaled therapy for treatment-resistan..
12/07 TESARO : Updates To Thesis
12/06 CLOVIS ONCOLOGY : 2018 Turnaround Story
12/06 BIOTECH ANALYSIS CENTRAL PHARMA NEWS : Galectin's Failure, Revance's Positive Re..
Financials ($)
Sales 2017 21 817 M
EBIT 2017 5 884 M
Net income 2017 2 293 M
Debt 2017 12 395 M
Yield 2017 4,26%
P/E ratio 2017 32,28
P/E ratio 2018 27,25
EV / Sales 2017 4,28x
EV / Sales 2018 4,28x
Capitalization 81 090 M
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 34
Average target price 68,3 $
Spread / Average Target 6,6%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA6.41%81 598
JOHNSON & JOHNSON21.23%377 698
NOVARTIS11.34%218 728
PFIZER9.48%213 036
ROCHE HOLDING LTD.6.19%208 877
MERCK AND COMPANY-7.68%151 559